Navigation Links
Pressure BioSciences, Inc. Provides Corporate Update
Date:9/24/2007

WEST BRIDGEWATER, Mass., Sept. 24 /PRNewswire-FirstCall/ -- Pressure BioSciences, Inc. (Nasdaq: PBIO) ("PBI") today provided an update on various corporate activities, including the expansion of its domestic sales force, the listing of its common stock on the Frankfurt Stock Exchange, and reaffirmation of guidance relative to forecasted FY2007 sales of the Company's Barocycler instruments.

1) Domestic Sales Force: the Company has hired four U.S. regional sales directors over the past month, increasing to six the number of full-time sales personnel it now has in the field. These four individuals all have strong educational backgrounds in the biological sciences, many years of experience working in (and often supervising) genomic or proteomic laboratories, and experience in selling capital equipment and/or consumable supplies into the research marketplace. The Company expects to hire at least one additional regional sales director during the next few weeks.

2) Frankfurt Stock Exchange: the Company's common stock is now listed on the Frankfurt Stock Exchange (FSE) with a trading symbol of BII.FSE and a WKN (German Security Code) of A0DJ09. The Frankfurt Stock Exchange is the third largest stock exchange in the world; shares traded on the FSE do not affect the Company's total shares outstanding.

3) Guidance on Barocycler Sales: the Company has reaffirmed its previously announced guidance concerning the Company's expectation to install a minimum of twenty (20) Barocycler units during the 2007 fiscal year.

About Pressure BioSciences, Inc.

Pressure BioSciences, Inc. (PBI) is a publicly traded company focused on the development of a novel, enabling, platform technology called Pressure Cycling Technology (PCT). PCT uses cycles of hydrostatic pressure between ambient and ultra-high levels (up to 35,000 psi and greater) to control bio-molecular interactions. PBI currently holds 13 US and 5 foreign patents covering multiple applications of PCT in the life sciences field, including such areas as genomic and proteomic sample preparation, pathogen inactivation, the control of chemical reactions (particularly enzymes), immunodiagnostics, and protein purification.

Forward Looking Statements

Statements contained in this press release regarding the Company's intentions, hopes, beliefs, expectations, or predictions of the future are "forward-looking" statements within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward looking statements include statements regarding the Company's expansion of its sales force; its listing on the Frankfurt Stock Exchange; and expected installations of Barocycler instruments during fiscal year 2007. These statements are based upon the Company's current expectations, forecasts, and assumptions that are subject to risks, uncertainties, and other factors that could cause actual outcomes and results to differ materially from those indicated by these forward-looking statements. These risks, uncertainties, and other factors include, but are not limited to: the possibility that the Company may not be successful in retaining the sales personnel that it has recently hired, or recruiting and retaining additional qualified sales personnel; the possibility that the Company may not be successful in maintaining a listing on the Frankfurt Stock Exchange, or that such listing may not be beneficial to the Company and its stockholders; risks and uncertainties concerning new product development, including the possibility that the Company may encounter unforeseen technological difficulties in the development of the PCT technology, the possibility that the Company's PCT products may not be accepted by the commercial market as a needed improvement over current extraction methods, or other difficulties that would prevent or otherwise impair the Company's ability to install at least twenty Barocycler units in fiscal year 2007; and the other risks and uncertainties discussed under the heading "Risk Factors" in the Company's Annual Report on Form 10-KSB for the year ended December 31, 2006, and other reports filed by the Company from time to time with the SEC. The Company undertakes no obligation to update any of the information included in this release, except as otherwise required by law.

Visit us at our website http://www.pressurebiosciences.com

Investor Contacts:

Richard T. Schumacher, President & CEO

Edward H. Myles, Sr. Vice President of Finance & CFO

Pressure BioSciences, Inc.

(508) 580-1818 (T)


'/>"/>
SOURCE Pressure BioSciences, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related biology technology :

1. The Analysis of Polycyclic Aromatic Hydrocarbons (PAHs) by LC/MS/MS Using an Atmospheric Pressure Photoionization Source
2. Determination of N-nitrosamines in Baby Bottle Rubber Teats by Liquid Chromatography-Atmospheric Pressure Chemical Ionization Mass Spectrometry
3. Screening of Corticosteroids in Urine by Negative Atmospheric Pressure Chemical Ionization LC/MS/MS
4. Medical College receives $11 million grant to study high blood pressure
5. Pressure mounts for Doyle to repeal shareholder liability law
6. Probe into gas gouging may educate Americans about pressures on oil supply
7. SWIB gets more pressure to invest in state tech start-ups
8. Technology puts pressure on old education methods
9. Effectene Transfection Reagent provides efficient gene delivery to primary neuronal cell cultures
10. TSKgel ODS-100Z and TSKgel ODS-100V column series provides a universal solution for the analysis of samples containing acidic, basic, polar & non-polar compounds
11. State provides $200K for Necedah ethanol plant
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/16/2017)... (PRWEB) , ... February 16, 2017 , ... Avomeen & ... The event will be held at Avomeen Analytical Services (4840 Venture Dr., Ann ... MichBio member organization. They provide an opportunity to interact with peers, make new connections ...
(Date:2/16/2017)... Calif. , Feb. 16, 2017  ArmaGen, ... developing groundbreaking therapies to treat severe neurological disorders, ... children treated with AGT-181, the company,s investigational therapy ... (also known as mucopolysaccharidosis type I, or MPS ... 2 proof-of-concept (POC) study, presented today at the ...
(Date:2/16/2017)... 16, 2017 Patient Care ... innovative telemedicine application, new and leading edge therapies ... a boom worldwide. The healthcare sector as whole ... services and new therapies for companies such as ... Cellectar Biosciences, Inc. (NASDAQ: CLRB ), ...
(Date:2/16/2017)... Malden, MA (PRWEB) , ... February 16, 2017 ... ... viscoelastic 4-level cervical case. Dr. Kingsley Chin, professor and Harvard trained surgeon, completed ... The procedure was performed on a 55-year-old practicing female physician suffering from degenerative ...
Breaking Biology Technology:
(Date:2/2/2017)... Feb. 2, 2017   TapImmune, Inc. ... company specializing in the development of innovative peptide ... of cancer and metastatic disease, announced today it ... manufacturing of a second clinical lot of TPIV ... receptor alpha. The manufactured vaccine product will be ...
(Date:1/30/2017)... , Jan. 30, 2017   Invitae Corporation ... fastest growing genetic information companies, today announced that it ... results and provide 2017 guidance on Monday, February 13, ... call that day at 4:45 p.m. Eastern / 1:45 ... management team will briefly review financial results, guidance, and ...
(Date:1/24/2017)... , Jan. 24, 2017  It sounds simple ... sock that monitors vital signs and alerts parents ... infant,s oxygen saturation level drops. But pediatric experts ... to parents, with no evidence of medical benefits, ... are marketed aggressively to parents of healthy babies, ...
Breaking Biology News(10 mins):